CDK7 inhibitors as anticancer drugs
2020 · Cancer and Metastasis Reviews · 194 citations
https://doi.org/10.1007/s10555-020-09885-8
G
Georgina P. Sava
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
38
Papers
830
Citations
10
h-index
11
i10-index
Georgina P. Sava is an academic researcher from The London College. The author has contributed to research in topics: Cancer-related Molecular Pathways & Chronic Lymphocytic Leukemia Research & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 10, co-authored 33 publications.
ORCID: 0000-0001-5904-3978Papers by this author
worksICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2018 · Molecular Cancer Therapeutics · 138 citations
https://doi.org/10.1158/1535-7163.mct-16-0847
Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia
2017 · Nature Communications · 101 citations
https://doi.org/10.1038/ncomms14175
Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism
2016 · Cell Reports · 66 citations
https://doi.org/10.1016/j.celrep.2016.07.053
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
2019 · Oncogene · 25 citations
https://doi.org/10.1038/s41388-019-1008-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat